• Dépistage, diagnostic, pronostic

  • Ressources et infrastructures

  • Foie

Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis

Menée auprès de 3 cohortes incluant respectivement 117, 34 et 79 patients présentant des métastases hépatiques ayant pour origine un cancer colorectal, cette étude met en évidence la présence dans le microenvironnement tumoral d'une grande concentration de lymphocytes CD8+ par rapport aux lymphocytes CD4+ chez les patients dont la croissance des métastases est de type desmoplastique

Background : Patients with resected colorectal liver metastasis (CRLM) who display only the desmoplastic histopathological growth pattern (dHGP) exhibit superior survival compared to patients with any non-desmoplastic growth (non-dHGP). The aim of this study was to compare the tumour microenvironment between dHGP and non-dHGP.

Methods : The tumour microenvironment was investigated in three cohorts of chemo-naive patients surgically treated for CRLM. In cohort A semi-quantitative immunohistochemistry was performed, in cohort B intratumoural and peritumoural T cells were counted using immunohistochemistry and digital image analysis, and in cohort C the relative proportions of individual T cell subsets were determined by flow cytometry.

Results : One hundred and seventeen, 34, and 79 patients were included in cohorts A, B, and C, with dHGP being observed in 27%, 29%, and 15% of patients, respectively. Cohorts A and B independently demonstrated peritumoural and intratumoural enrichment of cytotoxic CD8+ T cells in dHGP, as well as a higher CD8+/CD4+ ratio (cohort A). Flow cytometric analysis of fresh tumour tissues in cohort C confirmed these results; dHGP was associated with higher CD8+ and lower CD4+ T cell subsets, resulting in a higher CD8+/CD4+ ratio.

Conclusion : The tumour microenvironment of patients with dHGP is characterised by an increased and distinctly cytotoxic immune infiltrate, providing a potential explanation for their superior survival.

British Journal of Cancer , résumé, 2020

Voir le bulletin